APLM — Apollomics, Inc.

Summary of APLM Q4 2023 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: As of December 31, 2023, cash, cash equivalents, and market funds totaled $37.8 million, down from $58.9 million in 2022.
• Net Loss: The net loss for 2023 was $172.6 million ($2.32 per diluted share), a decrease from $240.8 million ($8.44 per diluted share) in 2022.
• R&D Expenses: Totaled $34.2 million for 2023, slightly down from $35.4 million in 2022. General and administrative expenses rose significantly to $20.6 million from $9.9 million due to costs associated with becoming a public company.
• Operating Cash Burn: Approximately $43.2 million used in operating activities, comparable to $42.8 million in 2022.

2. Strategic Updates and Business Highlights

• Product Development: Significant progress on lead drug candidates, Vebreltinib (APL-101) and APL-106. Vebreltinib is in advanced trials for non-small cell lung cancer (NSCLC) and glioblastoma.
• Clinical Trials: The SPARTA Trial has over 500 patients treated, showing promising efficacy for Vebreltinib. Interim data from the KUNPENG Trial also supports its potential in NSCLC.
• Regulatory Milestones: Conditional approval for Vebreltinib in China for NSCLC with MET Exon 14 skipping mutation was granted in December 2023. APL-106 is in a phase three bridging study for acute myeloid leukemia (AML), with top-line results expected in Q2 2024.

3. Forward Guidance and Outlook

• NDA Submission Timeline: Based on FDA feedback, Apollomics plans to continue patient enrollment in the SPARTA Trial, aiming for a potential NDA submission for Vebreltinib as early as 2025.
• Cash Runway: The current cash position is projected to fund operations through the first quarter of 2025. Future R&D expenses may increase due to ongoing clinical trials.

4. Bad News, Challenges, or Points of Concern

• Increased Expenses: Rising general and administrative costs due to public company status and stock-based compensation could pressure financials.
• Net Loss: Despite a reduction in net loss year-over-year, the company still faces significant financial challenges with a high cash burn rate.
• Regulatory Risks: The need for additional patient enrollment and data collection could delay NDA submissions, impacting timelines and potential revenue.

5. Notable Q&A Insights

• FDA Feedback: The FDA emphasized the need for continued patient enrollment to strengthen data for Vebreltinib, particularly for NSCLC indications.
• CFO's Role: Newly appointed CFO, Dr. Matthew Plunkett, aims to enhance financial strategy and operations, focusing on regulatory filings and capital formation.
• R&D Expense Projections: Analysts inquired about future R&D expenses, with indications that costs may rise due to ongoing clinical trials, but some expenses will decrease as certain trials conclude.

Overall, Apollomics demonstrated significant progress in clinical development and regulatory efforts, while also facing financial challenges and the need for strategic focus on key products.